Evaluation of the applicability and effectiveness of a molecular strategy for identifying weakD and DEL phenotype among D- blood donors of mixed origin exhibiting high frequency of RHD*

Carregando...
Imagem de Miniatura
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2018
Editora
WILEY
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
GUARDALINI, Luis Giovani O.
PESSOA, Elaine
LUZ, Fabio
NOVAC, Denise Rossite
GALLUCCI, Antonio
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
TRANSFUSION, v.58, n.2, p.317-322, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUNDMolecular tests designed to detect the presence of active RHD gene among D- donors have been successfully applied in people of European ancestry, but not in admixed populations with a considerable frequency of RHD*. Our goal was to evaluate the performance of a molecular screening tool for identifying active RHD alleles among Brazilian blood donors classified as D- C+ and/or E+. STUDY DESIGN AND METHODSPools of five DNA samples of serologically D- C+ and/or E+ donors were checked by a RHD polymerase chain reaction (PCR) assay specific for RHD Intron 4 and Exon 7. When a pool result was positive, samples were genotyped individually for RHD Intron 4 and Exon 7, RHD*, RHCE*Cc, and RHD zygosity. Donors suspected of active RHD gene were further evaluated by whole-coding region and flanking intron direct sequencing. RESULTSA total of 405 donors were included. Two percent exhibited active RHD gene, codifying D-weak (38 and 45) or DEL phenotype. The most prevalent DEL allele was RHD*DEL1 (c.1227G>A), which is proven to be immunogenic. A high frequency of RHD* was detected in the donors with nondeleted RHD alleles (31%), far superior to the frequency of RHD variant alleles (15.5%). The proposed approach presented sensitivity of 100% and specificity of 85.7% for identifying active RHD gene. CONCLUSIONThe strategy of checking D- donors with RHD PCR followed by exclusion of RHD* allele has proved efficient in identifying weak-D and DEL phenotype in the Brazilian population.
Palavras-chave
Referências
  1. Chiu RWK, 2001, CLIN CHEM, V47, P667
  2. COLIN Y, 1991, BLOOD, V78, P2747
  3. Dezan MR, 2017, BLOOD CELL MOL DIS, V65, P8, DOI 10.1016/j.bcmd.2017.03.014
  4. Dezan JVSB MR, 2016, ISBT SCI SERIES, V11, P132
  5. Flegel WA, 1998, TRANSFUSION MED, V8, P281
  6. Flegel WA, 2009, TRANSFUSION, V49, P465, DOI 10.1111/j.1537-2995.2008.01975.x
  7. Gowland P, 2014, TRANSFUS APHER SCI, V50, P163, DOI 10.1016/j.transci.2014.02.009
  8. Kim KH, 2009, KOREAN J LAB MED, V29, P361, DOI 10.3343/kjlm.2009.29.4.361
  9. Le Marechal C, 2007, TRANSFUSION, V47, P858, DOI 10.1111/j.1537-2995.2007.01200.x
  10. Mota M, 2012, J CLIN LAB ANAL, V26, P104, DOI 10.1002/jcla.21489
  11. Orzinska A, 2013, TRANSFUSION, V53, P2945, DOI 10.1111/trf.12230
  12. Pirelli KJ, 2010, PRENATAL DIAG, V30, P1207, DOI 10.1002/pd.2652
  13. Seo MH, 2016, VOX SANG, V111, P425, DOI 10.1111/vox.12450
  14. Shao CP, 2002, VOX SANG, V83, P156, DOI 10.1046/j.1423-0410.2002.00192.x
  15. Singleton BK, 2000, BLOOD, V95, P12
  16. Tax MGHM, 2002, TRANSFUSION, V42, P634, DOI 10.1046/j.1537-2995.2002.00096.x
  17. Wagner F F, 2004, Immunohematology, V20, P23
  18. Wagner FF, 1998, BLOOD, V91, P2157
  19. Wagner FF, 2013, TRANSFUS MED HEMOTH, V40, P172, DOI 10.1159/000351604
  20. Wagner FF, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-10
  21. Wagner T, 2005, TRANSFUSION, V45, P520, DOI 10.1111/j.0041-1132.2005.04256.x
  22. Yang HS, 2015, ANN LAB MED, V35, P554, DOI 10.3343/alm.2015.35.5.554
  23. Yasuda H, 2005, TRANSFUSION, V45, P1581, DOI 10.1111/j.1537-2995.2005.00579.x